Study analysis · Frontiers in Medicine · 2026
Hormone therapy didn't just help women feel better—it made their bones stronger AND didn't increase breast cancer risk, according to a 2-year study of 809 women.
Taking hormone therapy for two years helped women stop losing bone, feel way less hot and moody, and didn't cause any new breast lumps.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched a group of women who decided to take hormone pills for 2 years and noticed their bones got stronger and hot flashes got better. But we don’t know if the pills caused it — maybe those women were already eating better or exercising more. So we can only say the pills and the improvements happened together, not that one caused the other.
What’s the bottom line?
This study looked at women who took hormone pills or patches after menopause to see if it helped their bones and symptoms.
How strong is this study?
This study did a good job measuring things like bone density and symptoms carefully over time, and followed most women until the end. But it’s like watching only kids who chose to eat broccoli and saying broccoli makes you strong — we don’t know if the kids who didn’t eat broccoli would’ve been weaker. That’s why we can’t be totally sure the results are because of the treatment.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
37 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=809)+19.6/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or a control group, so it cannot rule out confounding factors such as lifestyle, diet, or pre-existing health behaviors that may have influenced the outcomes. The lack of randomization means we cannot conclude that MHT caused the observed changes.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text. The study appears independently conducted by a public hospital with no industry ties identified.
Independent Analysis Safeguards
- Study approved by Medical Ethics Committee of Hunan Provincial Maternal and Child Health Hospital
- Statistical analysis performed using SPSS with Bonferroni correction
- BMD and mammography measurements followed standardized protocols with quality control measures
The study was conducted at a public hospital and used standard clinical tools (DEXA, Hologic mammography) without mention of industry sponsorship, author industry affiliations, or funder involvement in design, analysis, or publication. No conflicts of interest were disclosed, but absence of a COI section means it cannot be confirmed whether one was omitted.
Key takeaways
- 01
After 2 years, 18% of women had osteoporosis — that dropped to 14%.
- 02
Their hot flash and mood scores fell from 40 to 11.
- 03
Breast scans showed no new lumps or density changes.
- 04
Yes — fewer broken bones, much less discomfort, and no signs of breast harm in 2 years.
Surprising findings
- Breast tissue showed no measurable changes despite estrogen exposure.Most people assume estrogen increases breast cancer risk by thickening tissue—but here, density and mass rates stayed flat for two years, even as symptoms improved.
- Symptom relief continued improving slowly after the first year.Most expect quick fixes—this study shows the biggest gains aren't in the first 6 months, but in months 12–18, suggesting long-term use has hidden benefits.
Practical takeaways
If you're experiencing menopausal symptoms and have no contraindications, consider starting hormone therapy—bone and symptom benefits are clear by 6 months, and breast safety looks good within 2 years.
This study only followed women for 2 years and excluded those with prior cancer, blood clots, or liver disease. Long-term risks beyond 5 years remain unknown.
high confidenceWhy this study matters
Bones Got Stronger—Fast
After 24 months of hormone therapy, osteoporosis dropped from 18% to 14% and osteopenia fell from 27.4% to 21.4%—with the biggest bone density gains happening in the first year. DEXA scans showed statistically significant improvements at every check-in (p < 0.001).
Most women think bone loss is inevitable after menopause—this shows it’s reversible with the right treatment, potentially preventing fractures and hospital visits.
Hot Flashes Vanished—But Not Overnight
Kuppermann symptom scores plummeted from 40.17 to 11.38—a 72% drop—but the biggest improvement happened in the first 6 months (down to 26.9), then kept slowly improving. The steepest drop was between months 12 and 18.
Women often quit hormone therapy if they don't feel better immediately—this proves the full benefit takes 18+ months, encouraging persistence.
No Breast Cancer Red Flags—Despite the Fear
Breast density, volume, and mass prevalence showed no statistically significant changes over 24 months (all p > 0.05). Mammograms found no increase in calcifications or lumps—even as symptoms improved.
This directly challenges the widespread fear that hormone therapy = breast cancer. For many women, this could be the deciding factor to start treatment.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at women who took hormone pills or patches after menopause to see if it helped their bones and symptoms.
Research results
After 2 years, 18% of women had osteoporosis — that dropped to 14%. Their hot flash and mood scores fell from 40 to 11. Breast scans showed no new lumps or density changes.
What this means - more context
Yes — fewer broken bones, much less discomfort, and no signs of breast harm in 2 years.
This study evaluated the 24-month effects of menopausal hormone therapy (MHT) on bone mineral density, menopausal symptoms, and breast safety in postmenopausal women.
MHT significantly improved bone mineral density and reduced menopausal symptom severity over 24 months, with no detectable adverse changes in breast morphology or lesion prevalence during the study period.
Methods Used
Prospective cohort study of 809 postmenopausal women aged 40–60 receiving MHT; outcomes (BMD, Kuppermann scores, breast imaging) were measured at baseline and 6, 12, 18, and 24 months using DEXA, mammography, and validated scales with Bonferroni-corrected statistical analysis.
Main Finding
MHT reduced osteoporosis prevalence from 18.0% to 14.0% (p < 0.001) and osteopenia from 27.4% to 21.4% (p < 0.001); Kuppermann scores dropped from 40.17 ± 6.04 to 11.38 ± 4.90 (p < 0.001); no significant changes in breast density, volume, or lesion prevalence (all p > 0.05).
Confidence Level
High — large sample size (n=809), longitudinal design with repeated measures, validated tools, and rigorous statistical correction for multiple comparisons.
Study Flags
Red Flags
- •No control group
- •No randomization
- •Limited to Chinese urban, high-income women — may not generalize
Surprising Findings
Breast tissue showed no measurable changes despite estrogen exposure.
Most people assume estrogen increases breast cancer risk by thickening tissue—but here, density and mass rates stayed flat for two years, even as symptoms improved.
Practical Takeaways
If you're experiencing menopausal symptoms and have no contraindications, consider starting hormone therapy—bone and symptom benefits are clear by 6 months, and breast safety looks good within 2 years.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched a group of women who decided to take hormone pills for 2 years and noticed their bones got stronger and hot flashes got better. But we don’t know if the pills caused it — maybe those women were already eating better or exercising more. So we can only say the pills and the improvements happened together, not that one caused the other.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (n=809) with high follow-up rate (87.5%)
- Longitudinal design with multiple time points over 24 months
- Use of validated tools (Kuppermann score, DEXA, mammography)
Weaknesses
- No control group (non-MHT users) for comparison
- No randomization — participants self-selected into MHT
- Blinding was unknown and likely not used
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at women who took hormone pills or patches after menopause to see if it helped their bones and symptoms.
Research results
After 2 years, 18% of women had osteoporosis — that dropped to 14%. Their hot flash and mood scores fell from 40 to 11. Breast scans showed no new lumps or density changes.
What this means - more context
Yes — fewer broken bones, much less discomfort, and no signs of breast harm in 2 years.
This study evaluated the 24-month effects of menopausal hormone therapy (MHT) on bone mineral density, menopausal symptoms, and breast safety in postmenopausal women.
MHT significantly improved bone mineral density and reduced menopausal symptom severity over 24 months, with no detectable adverse changes in breast morphology or lesion prevalence during the study period.
Methods Used
Prospective cohort study of 809 postmenopausal women aged 40–60 receiving MHT; outcomes (BMD, Kuppermann scores, breast imaging) were measured at baseline and 6, 12, 18, and 24 months using DEXA, mammography, and validated scales with Bonferroni-corrected statistical analysis.
Main Finding
MHT reduced osteoporosis prevalence from 18.0% to 14.0% (p < 0.001) and osteopenia from 27.4% to 21.4% (p < 0.001); Kuppermann scores dropped from 40.17 ± 6.04 to 11.38 ± 4.90 (p < 0.001); no significant changes in breast density, volume, or lesion prevalence (all p > 0.05).
Confidence Level
High — large sample size (n=809), longitudinal design with repeated measures, validated tools, and rigorous statistical correction for multiple comparisons.
Study Flags
Red Flags
- •No control group
- •No randomization
- •Limited to Chinese urban, high-income women — may not generalize
Surprising Findings
Breast tissue showed no measurable changes despite estrogen exposure.
Most people assume estrogen increases breast cancer risk by thickening tissue—but here, density and mass rates stayed flat for two years, even as symptoms improved.
Practical Takeaways
If you're experiencing menopausal symptoms and have no contraindications, consider starting hormone therapy—bone and symptom benefits are clear by 6 months, and breast safety looks good within 2 years.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study watched a group of women who decided to take hormone pills for 2 years and noticed their bones got stronger and hot flashes got better. But we don’t know if the pills caused it — maybe those women were already eating better or exercising more. So we can only say the pills and the improvements happened together, not that one caused the other.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (n=809) with high follow-up rate (87.5%)
- Longitudinal design with multiple time points over 24 months
- Use of validated tools (Kuppermann score, DEXA, mammography)
Weaknesses
- No control group (non-MHT users) for comparison
- No randomization — participants self-selected into MHT
- Blinding was unknown and likely not used
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study did a good job measuring things like bone density and symptoms carefully over time, and followed most women until the end. But it’s like watching only kids who chose to eat broccoli and saying broccoli makes you strong — we don’t know if the kids who didn’t eat broccoli would’ve been weaker. That’s why we can’t be totally sure the results are because of the treatment.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
37 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=809)+19.6/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or a control group, so it cannot rule out confounding factors such as lifestyle, diet, or pre-existing health behaviors that may have influenced the outcomes. The lack of randomization means we cannot conclude that MHT caused the observed changes.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text. The study appears independently conducted by a public hospital with no industry ties identified.
Independent Analysis Safeguards
- Study approved by Medical Ethics Committee of Hunan Provincial Maternal and Child Health Hospital
- Statistical analysis performed using SPSS with Bonferroni correction
- BMD and mammography measurements followed standardized protocols with quality control measures
The study was conducted at a public hospital and used standard clinical tools (DEXA, Hologic mammography) without mention of industry sponsorship, author industry affiliations, or funder involvement in design, analysis, or publication. No conflicts of interest were disclosed, but absence of a COI section means it cannot be confirmed whether one was omitted.